Form DEF 14A ACURA PHARMACEUTICALS, For: May 25
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities
Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x | Definitive Proxy Statement |
| ¨ | Definitive Additional Materials |
| ¨ | Soliciting Material Pursuant to § 240.14a-12 |
ACURA PHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| o | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: | |
| (2) | Aggregate number of securities to which transaction applies: | |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |
| (4) | Proposed maximum aggregate value of transaction: | |
| (5) | Total fee paid: | |
| ¨ | Fee paid previously with preliminary materials. |
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: | |
| (2) | Form, Schedule or Registration Statement no.: | |
ACURA PHARMACEUTICALS, INC.
616 N. North Court, Suite 120
Palatine, Illinois 60067
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
Notice is hereby given that the 2021 Annual Meeting
of Shareholders (the “Meeting”) of Acura Pharmaceuticals, Inc., a New York corporation (the “Company”), will
be held at Sills Cummis & Gross, One Riverfront Plaza, 1037 Raymond Blvd., Newark, NJ 07102 on May 25, 2021 at 9:30 a.m.,
Eastern Time, for the purposes listed below:
1. To elect five directors to the Board
of Directors who shall serve until the 2022 Annual Meeting of Shareholders, or until their successors have been elected and qualified;
2. To cast a non-binding advisory vote
on executive compensation (“say-on-pay”);
3. To adopt the Company’s 2021
Restricted Stock Unit Award Plan;
4. To ratify the appointment of BDO
USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and
5. To transact such other business
as may properly come before the Meeting or any adjournment thereof.
Only shareholders of record
at the close of business on March 29, 2021 are entitled to notice of and to vote at the Meeting or any adjournment thereof.
We are pleased to take advantage
of the U.S. Securities and Exchange Commission rule that allows companies to furnish proxy materials to their shareholders over the
Internet. As a result, we are mailing to our shareholders a Notice of Internet Availability of Proxy Materials (the “Notice”)
instead of paper copies of this proxy statement and our 2020 Annual Report. We believe this process allows us to provide our shareholders
with the required information more promptly, reduces adverse environmental impact, and reduces costs associated with printing and distributing
our proxy materials. The Notice contains instructions on how to access our Proxy Statement and…
Read More: Form DEF 14A ACURA PHARMACEUTICALS, For: May 25